Dose optimisation and scarce resource allocation: two sides of the same coin.
Where this comes from
- Record sourced from PubMed, PMID 36223969.
- Also identified by DOI 10.1136/bmjopen-2022-063436 and PMC identifier 9562718.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A deep understanding of the relationship between a scarce drug's dose and clinical response is necessary to appropriately distribute a supply-constrained drug along these lines. The vast majority of drug development and repurposing during the COVID-19 pandemic - an event that has made clear the ever-present scarcity in healthcare systems -has been ignorant of scarcity and dose optimisation's ability to help address it. Future pandemic clinical trials systems should obtain dose optimisation data, as these appear necessary to enable appropriate scarce resource allocation according to societal values.
Medical subject headings
- COVID-19
- Pandemics